ROLE OF CANCER IMMUNOTHERAPY IN ADVANCED STAGE OF NON-SMAL CELL LUNG CANCER: REVIEW ARTICLE
Safat S, Wei YC*, Lu D, Zhou FL and Tian Y
Among all cancer, 80 -85% accounts for lung cancer and among this 30% is lung cancer with stage III. Lung cancer is the second most common cancer being diagnosed in both the genders after prostate in men and breast cancer in women. Patient with Non-Small Cell Lung Cancer (NSCLC) usually presents with locally advanced or metastatic cancer at the time of diagnosis. The major risk factor for the aetiology of lung cancer is cigarette smoking although many other risk factors have been identified. Lung cancer can be classified into two types manly: Small cell Lung Cancer and Non-Small Cell Lung Cancer. As this is a highly fatal and complicated type of cancer, it is extremely important to identify the cancer in its early stages in order to achieve a curative mode of treatment, but unfortunately the patient most of the time presents with advanced or metastatic disease at the time they seek treatment. For this purpose, many treatment modalities have been emerged recently to battle this stage and the treatment modality is chemotherapy combinations with two or more drugs with the main aim of improving the 5 year survival rate in these patients.
[Full Text Article]